Screener
BioMarin Pharmaceuticals BMRN Research and early pipeline — R&D
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by BioMarin Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The source filing: BioMarin Pharmaceuticals’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:14 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001048477-26-000016
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Less: | ||||
| Cost of sales | 202,795 | 150,090 | 397,794 | 301,648 |
| R&D expenses | ||||
| Research and early pipeline | 85,069 | 95,968 | 172,360 | 186,438 |
| Later-stage clinical programs | 50,295 | 13,133 | 86,472 | 27,424 |
| Marketed products | 71,588 | 52,207 | 126,916 | 106,177 |
| SG&A expenses | ||||
| S&M expenses | 142,186 | 122,100 | 267,113 | 224,631 |
Item 1. Financial Statements
FAQ
- What is BioMarin Pharmaceuticals's research and early pipeline — R&D?
- BioMarin Pharmaceuticals (BMRN) reported research and early pipeline — R&D of $85.07M in Q2 2026.
- How has BioMarin Pharmaceuticals's research and early pipeline — R&D changed year-over-year?
- BioMarin Pharmaceuticals's research and early pipeline — R&D decreased by 11.4% year-over-year, from $95.97M to $85.07M.
- What is the long-term trend for BioMarin Pharmaceuticals's research and early pipeline — R&D?
- Over 3 years (2022 to 2025), BioMarin Pharmaceuticals's research and early pipeline — R&D has grown at a 6.9% compound annual growth rate (CAGR), from $313.92M to $383.71M.
- What does research and early pipeline — R&D mean?
- This metric represents the total operating expenses dedicated to research and early-stage development activities within the company's pipeline. It encompasses costs associated with discovery, preclinical studies, and early clinical trials aimed at identifying and validating new therapeutic candidates before they reach late-stage development. This expenditure is critical for assessing the company's long-term innovation capacity and the sustainability of its future product portfolio.
Ask your AI about BioMarin Pharmaceuticals's research and early pipeline — r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude